![Zyprexa 1% - image 0](/style/images/medicines/zyprexa-1/pic1.jpg)
![Zyprexa 1% - image 1](/style/images/medicines/zyprexa-1/pic10.jpg)
![Zyprexa 1% - image 2](/style/images/medicines/zyprexa-1/pic11.jpg)
![Zyprexa 1% - image 3](/style/images/medicines/zyprexa-1/pic12.jpg)
![Zyprexa 1% - image 4](/style/images/medicines/zyprexa-1/pic13.jpg)
![Zyprexa 1% - image 5](/style/images/medicines/zyprexa-1/pic14.jpg)
![Zyprexa 1% - image 6](/style/images/medicines/zyprexa-1/pic15.jpg)
![Zyprexa 1% - image 7](/style/images/medicines/zyprexa-1/pic16.jpg)
![Zyprexa 1% - image 8](/style/images/medicines/zyprexa-1/pic17.jpg)
![Zyprexa 1% - image 9](/style/images/medicines/zyprexa-1/pic18.jpg)
![Zyprexa 1% - image 10](/style/images/medicines/zyprexa-1/pic19.jpg)
![Zyprexa 1% - image 11](/style/images/medicines/zyprexa-1/pic2.jpg)
![Zyprexa 1% - image 12](/style/images/medicines/zyprexa-1/pic20.jpg)
![Zyprexa 1% - image 13](/style/images/medicines/zyprexa-1/pic21.jpg)
![Zyprexa 1% - image 14](/style/images/medicines/zyprexa-1/pic22.jpg)
![Zyprexa 1% - image 15](/style/images/medicines/zyprexa-1/pic23.jpg)
![Zyprexa 1% - image 16](/style/images/medicines/zyprexa-1/pic24.jpg)
![Zyprexa 1% - image 17](/style/images/medicines/zyprexa-1/pic3.jpg)
![Zyprexa 1% - image 18](/style/images/medicines/zyprexa-1/pic4.jpg)
![Zyprexa 1% - image 19](/style/images/medicines/zyprexa-1/pic5.jpg)
![Zyprexa 1% - image 20](/style/images/medicines/zyprexa-1/pic6.jpg)
![Zyprexa 1% - image 21](/style/images/medicines/zyprexa-1/pic7.jpg)
![Zyprexa 1% - image 22](/style/images/medicines/zyprexa-1/pic8.jpg)
![Zyprexa 1% - image 23](/style/images/medicines/zyprexa-1/pic9.jpg)
Components:
Method of action:
Treatment option:
Medically reviewed by Oliinyk Elizabeth Ivanovna, PharmD. Last updated on 12.03.2022
![](/style/images/attention_blue.png)
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Top 20 medicines with the same components:
Top 20 medicines with the same treatments:
Dosage Forms And Strengths
The ZYPREXA 2.5 mg, 5 mg, 7.5 mg, and 10 mg tablets are white, round, and imprinted in blue ink with LILLY and tablet number. The 15 mg tablets are elliptical, blue, and debossed with LILLY and tablet number. The 20 mg tablets are elliptical, pink, and debossed with LILLY and tablet number. Tablets are not scored. The tablets are available as follows:
TABLET STRENGTH | ||||||
2.5 mg | 5 mg | 7.5 mg | 10 mg | 15 mg | 20 mg | |
Tablet No. Identification | 4112 | 4115 | 4116 | 4117 | 4415 | 4420 |
LILLY | LILLY | LILLY | LILLY | LILLY | LILLY | |
4112 | 4115 | 4116 | 4117 | 4415 | 4420 |
ZYPREXA ZYDIS (olanzapine orally disintegrating tablets) are yellow, round, and debossed with the tablet strength. Tablets are not scored. The tablets are available as follows:
ZYPREXA ZYDIS Tablets | TABLET STRENGTH | |||
5 mg | 10 mg | 15 mg | 20 mg | |
Tablet No.Debossed | 4453 | 4454 | 4455 | 4456 |
5 | 10 | 15 | 20 |
ZYPREXA IntraMuscular is available in 10 mg vial (1s).
The ZYPREXA 2.5 mg, 5 mg, 7.5 mg, and 10 mg tablets are white, round, and imprinted in blue ink with LILLY and tablet number. The 15 mg tablets are elliptical, blue, and debossed with LILLY and tablet number. The 20 mg tablets are elliptical, pink, and debossed with LILLY and tablet number. The tablets are available as follows:
TABLET STRENGTH | ||||||
2.5 mg | 5 mg | 7.5 mg | 10 mg | 15 mg | 20 mg | |
Tablet No. Identification | 4112 | 4115 | 4116 | 4117 | 4415 | 4420 |
LILLY | LILLY | LILLY | LILLY | LILLY | LILLY | |
NDC Codes Bottles 30 | 4112 | 4115 | 4116 | 4117 | 4415 | 4420 |
NDC 0002- | NDC 0002- | NDC 0002- | NDC 0002- | NDC 0002- | NDC 0002- | |
4112-30 | 4115-30 | 4116-30 | 4117-30 | 4415-30 | 4420-30 |
ZYPREXA ZYDIS (olanzapine orally disintegrating tablets) are yellow, round, and debossed with the tablet strength. The tablets are available as follows:
ZYPREXA ZYDIS Tablets | TABLET STRENGTH | |||
5 mg | 10 mg | 15 mg | 20 mg | |
Tablet No. | 4453 | 4454 | 4455 | 4456 |
Debossed | 5 | 10 | 15 | 20 |
NDC Codes: | ||||
Dose Pack 30 (Child Resistant) | NDC 0002-4453-85 | NDC 0002-4454-85 | NDC 0002-4455-85 | NDC 0002-4456-85 |
ZYPREXA IntraMuscular is available in:
NDC 0002-7597-01 (No. VL7597) - 10 mg vial (1s)
Storage And Handling
Store ZYPREXA tablets, ZYPREXA ZYDIS, and ZYPREXA IntraMuscular vials (before reconstitution) at controlled room temperature, 20° to 25°C (68° to 77°F). Reconstituted ZYPREXA IntraMuscular may be stored at controlled room temperature, 20° to 25°C (68° to 77°F) for up to 1 hour if necessary. Discard any unused portion of reconstituted ZYPREXA IntraMuscular. The USP defines controlled room temperature as a temperature maintained thermostatically that encompasses the usual and customary working environment of 20° to 25°C (68° to 77°F); that results in a mean kinetic temperature calculated to be not more than 25°C; and that allows for excursions between 15° and 30°C (59° and 86°F) that are experienced in pharmacies, hospitals, and warehouses.
Protect ZYPREXA tablets and ZYPREXA ZYDIS from light and moisture. Protect ZYPREXA IntraMuscular from light, do not freeze.
Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA. Revised: Feb 2017
Schizophrenia
Oral ZYPREXA is indicated for the treatment of schizophrenia. Efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. In adolescent patients with schizophrenia (ages 13-17), efficacy was established in one 6-week trial.
When deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. Clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents.
Bipolar I Disorder (Manic or Mixed Episodes)
Monotherapy
Oral ZYPREXA is indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. Efficacy was established in three clinical trials in adult patients with manic or mixed episodes of bipolar I disorder: two 3-to 4-week trials and one monotherapy maintenance trial. In adolescent patients with manic or mixed episodes associated with bipolar I disorder (ages 13-17), efficacy was established in one 3-week trial.
When deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. Clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents.
Adjunctive Therapy To Lithium Or Valproate
Oral ZYPREXA is indicated for the treatment of manic or mixed episodes associated with bipolar I disorder as an adjunct to lithium or valproate. Efficacy was established in two 6-week clinical trials in adults. The effectiveness of adjunctive therapy for longer-term use has not been systematically evaluated in controlled trials.
Special Considerations In Treating Pediatric Schizophrenia And Bipolar I Disorder
Pediatric schizophrenia and bipolar I disorder are serious mental disorders; however, diagnosis can be challenging. For pediatric schizophrenia, symptom profiles can be variable, and for bipolar I disorder, pediatric patients may have variable patterns of periodicity of manic or mixed symptoms. It is recommended that medication therapy for pediatric schizophrenia and bipolar I disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment. Medication treatment for both pediatric schizophrenia and bipolar I disorder should be part of a total treatment program that often includes psychological, educational and social interventions.
ZYPREXA IntraMuscular: Agitation Associated With Schizophrenia And Bipolar I Mania
ZYPREXA IntraMuscular is indicated for the treatment of acute agitation associated with schizophrenia and bipolar I mania. Efficacy was demonstrated in 3 short-term (24 hours of IM treatment) placebo-controlled trials in agitated adult inpatients with: schizophrenia or bipolar I disorder (manic or mixed episodes).
“Psychomotor agitation” is defined in DSM-IV as “excessive motor activity associated with a feeling of inner tension.” Patients experiencing agitation often manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors, escalating or urgently distressing behavior, or self-exhausting behavior, leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the agitation.
ZYPREXA And Fluoxetine In Combination: Depressive Episodes Associated With Bipolar I Disorder
Oral ZYPREXA and fluoxetine in combination is indicated for the treatment of depressive episodes associated with bipolar I disorder, based on clinical studies. W hen using ZYPREXA and fluoxetine in combination, refer to the Clinical Studies section of the package insert for Symbyax.
ZYPREXA monotherapy is not indicated for the treatment of depressive episodes associated with bipolar I disorder.
ZYPREXA And Fluoxetine In Combination: Treatment Resistant Depression
Oral ZYPREXA and fluoxetine in combination is indicated for the treatment of treatment resistant depression (major depressive disorder in patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode), based on clinical studies in adult patients. When using ZYPREXA and fluoxetine in combination, refer to the Clinical Studies section of the package insert for Symbyax.
ZYPREXA monotherapy is not indicated for the treatment of treatment resistant depression.
Schizophrenia
Adults
Dose Selection
Oral olanzapine should be administered on a once-a-day schedule without regard to meals, generally beginning with 5 to 10 mg initially, with a target dose of 10 mg/day within several days. Further dosage adjustments, if indicated, should generally occur at intervals of not less than 1 week, since steady state for olanzapine would not be achieved for approximately 1 week in the typical patient. When dosage adjustments are necessary, dose increments/decrements of 5 mg QD are recommended.
Efficacy in schizophrenia was demonstrated in a dose range of 10 to 15 mg/day in clinical trials. However, doses above 10 mg/day were not demonstrated to be more efficacious than the 10 mg/day dose. An increase to a dose greater than the target dose of 10 mg/day (i.e., to a dose of 15 mg/day or greater) is recommended only after clinical assessment. Olanzapine is not indicated for use in doses above 20 mg/day.
Dosing In Special Populations
The recommended starting dose is 5 mg in patients who are debilitated, who have a predisposition to hypotensive reactions, who otherwise exhibit a combination of factors that may result in slower metabolism of olanzapine (e.g., nonsmoking female patients ≥ 65 years of age), or who may be more pharmacodynamically sensitive to olanzapine. When indicated, dose escalation should be performed with caution in these patients.
Maintenance Treatment
The effectiveness of oral olanzapine, 10 mg/day to 20 mg/day, in maintaining treatment response in schizophrenic patients who had been stable on ZYPREXA for approximately 8 weeks and were then followed for relapse has been demonstrated in a placebo-controlled trial. The physician who elects to use ZYPREXA for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient.
Adolescents
Dose Selection
Oral olanzapine should be administered on a once-a-day schedule without regard to meals with a recommended starting dose of 2.5 or 5 mg, with a target dose of 10 mg/day. Efficacy in adolescents with schizophrenia was demonstrated based on a flexible dose range of 2.5 to 20 mg/day in clinical trials, with a mean modal dose of 12.5 mg/day (mean dose of 11.1 mg/day). When dosage adjustments are necessary, dose increments/decrements of 2.5 or 5 mg are recommended. The safety and effectiveness of doses above 20 mg/day have not been evaluated in clinical trials.
Maintenance Treatment
The efficacy of ZYPREXA for the maintenance treatment of schizophrenia in the adolescent population has not been systematically evaluated; however, maintenance efficacy can be extrapolated from adult data along with comparisons of olanzapine pharmacokinetic parameters in adult and adolescent patients. Thus, it is generally recommended that responding patients be continued beyond the acute response, but at the lowest dose needed to maintain remission. Patients should be periodically reassessed to determine the need for maintenance treatment.
Bipolar I Disorder (Manic or Mixed Episodes)
Adults
Dose Selection For Monotherapy
Oral olanzapine should be administered on a once-a-day schedule without regard to meals, generally beginning with 10 or 15 mg. Dosage adjustments, if indicated, should generally occur at intervals of not less than 24 hours, reflecting the procedures in the placebo-controlled trials. When dosage adjustments are necessary, dose increments/decrements of 5 mg QD are recommended.
Short-term (3-4 weeks) antimanic efficacy was demonstrated in a dose range of 5 mg to 20 mg/day in clinical trials. The safety of doses above 20 mg/day has not been evaluated in clinical trials.
Maintenance Monotherapy
The benefit of maintaining bipolar I patients on monotherapy with oral ZYPREXA at a dose of 5 to 20 mg/day, after achieving a responder status for an average duration of 2 weeks, was demonstrated in a controlled trial. The physician who elects to use ZYPREXA for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient.
Dose Selection For Adjunctive Treatment
W hen administered as adjunctive treatment to lithium or valproate, oral olanzapine dosing should generally begin with 10 mg once-a-day without regard to meals. Antimanic efficacy was demonstrated in a dose range of 5 mg to 20 mg/day in clinical trials. The safety of doses above 20 mg/day has not been evaluated in clinical trials.
Adolescents
Dose Selection
Oral olanzapine should be administered on a once-a-day schedule without regard to meals with a recommended starting dose of 2.5 or 5 mg, with a target dose of 10 mg/day. Efficacy in adolescents with bipolar I disorder (manic or mixed episodes) was demonstrated based on a flexible dose range of 2.5 to 20 mg/day in clinical trials, with a mean modal dose of 10.7 mg/day (mean dose of 8.9 mg/day). W hen dosage adjustments are necessary, dose increments/decrements of 2.5 or 5 mg are recommended.
The safety and effectiveness of doses above 20 mg/day have not been evaluated in clinical trials.
Maintenance Treatment
The efficacy of ZYPREXA for the maintenance treatment of bipolar I disorder in the adolescent population has not been evaluated; however, maintenance efficacy can be extrapolated from adult data along with comparisons of olanzapine pharmacokinetic parameters in adult and adolescent patients. Thus, it is generally recommended that responding patients be continued beyond the acute response, but at the lowest dose needed to maintain remission. Patients should be periodically reassessed to determine the need for maintenance treatment.
Administration Of ZYPREXA ZYDIS (olanzapine orally disintegrating tablets)
After opening sachet, peel back foil on blister. Do not push tablet through foil. Immediately upon opening the blister, using dry hands, remove tablet and place entire ZYPREXA ZYDIS in the mouth. Tablet disintegration occurs rapidly in saliva so it can be easily swallowed with or without liquid.
ZYPREXA IntraMuscular: Agitation Associated With Schizophrenia And Bipolar I Mania
Dose Selection For Agitated Adult Patients With Schizophrenia And Bipolar I Mania
The efficacy of intramuscular olanzapine for injection in controlling agitation in these disorders was demonstrated in a dose range of 2.5 mg to 10 mg. The recommended dose in these patients is 10 mg. A lower dose of 5 or 7.5 mg may be considered when clinical factors warrant. If agitation warranting additional intramuscular doses persists following the initial dose, subsequent doses up to 10 mg may be given. However, the efficacy of repeated doses of intramuscular olanzapine for injection in agitated patients has not been systematically evaluated in controlled clinical trials. Also, the safety of total daily doses greater than 30 mg, or 10 mg injections given more frequently than 2 hours after the initial dose, and 4 hours after the second dose have not been evaluated in clinical trials. Maximal dosing of intramuscular olanzapine (e.g., 3 doses of 10 mg administered 2-4 hours apart) may be associated with a substantial occurrence of significant orthostatic hypotension. Thus, it is recommended that patients requiring subsequent intramuscular injections be assessed for orthostatic hypotension prior to the administration of any subsequent doses of intramuscular olanzapine for injection. The administration of an additional dose to a patient with a clinically significant postural change in systolic blood pressure is not recommended.
If ongoing olanzapine therapy is clinically indicated, oral olanzapine may be initiated in a range of 5-20 mg/day as soon as clinically appropriate.
Intramuscular Dosing In Special Populations
A dose of 5 mg/injection should be considered for geriatric patients or when other clinical factors warrant. A lower dose of 2.5 mg/injection should be considered for patients who otherwise might be debilitated, be predisposed to hypotensive reactions, or be more pharmacodynamically sensitive to olanzapine.
Administration Of ZYPREXA IntraMuscular
ZYPREXA IntraMuscular is intended for intramuscular use only. Do not administer intravenously or subcutaneously. Inject slowly, deep into the muscle mass.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Directions For Preparation Of ZYPREXA IntraMuscular With Sterile Water For Injection
Dissolve the contents of the vial using 2.1 mL of Sterile Water for Injection to provide a solution containing approximately 5 mg/mL of olanzapine. The resulting solution should appear clear and yellow. ZYPREXA IntraMuscular reconstituted with Sterile Water for Injection should be used immediately (within 1 hour) after reconstitution. Discard any unused portion.
The following table provides injection volumes for delivering various doses of intramuscular olanzapine for injection reconstituted with Sterile Water for Injection.
Dose, ma Olanzapine | Volume of Injection, mL |
10 | Withdraw total contents of vial |
7.5 | 1.5 |
5 | 1 |
2.5 | 0.5 |
Physical Incompatibility Information
ZYPREXA IntraMuscular should be reconstituted only with Sterile Water for Injection. ZYPREXA IntraMuscular should not be combined in a syringe with diazepam injection because precipitation occurs when these products are mixed. Lorazepam injection should not be used to reconstitute ZYPREXA IntraMuscular as this combination results in a delayed reconstitution time. ZYPREXA IntraMuscular should not be combined in a syringe with haloperidol injection because the resulting low pH has been shown to degrade olanzapine over time.
ZYPREXA And Fluoxetine In Combination: Depressive Episodes Associated With Bipolar I Disorder
When using ZYPREXA and fluoxetine in combination, also refer to the Clinical Studies section of the package insert for Symbyax.
Adults
Oral olanzapine should be administered in combination with fluoxetine once daily in the evening, without regard to meals, generally beginning with 5 mg of oral olanzapine and 20 mg of fluoxetine. Dosage adjustments, if indicated, can be made according to efficacy and tolerability within dose ranges of oral olanzapine 5 to 12.5 mg and fluoxetine 20 to 50 mg. Antidepressant efficacy was demonstrated with ZYPREXA and fluoxetine in combination in adult patients with a dose range of olanzapine 6 to 12 mg and fluoxetine 25 to 50 mg. Safety of co-administration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in clinical studies.
Children And Adolescents (10-17 years of age)
Oral olanzapine should be administered in combination with fluoxetine once daily in the evening, without regard to meals, generally beginning with 2.5 mg of oral olanzapine and 20 mg of fluoxetine. Dosage adjustments, if indicated, can be made according to efficacy and tolerability. Safety of co-administration of doses above 12 mg olanzapine with 50 mg fluoxetine has not been evaluated in pediatric clinical studies.
Safety and efficacy of ZYPREXA and fluoxetine in combination was determined in clinical trials supporting approval of Symbyax (fixed dose combination of ZYPREXA and fluoxetine). Symbyax is dosed between 3 mg/25 mg (olanzapine/fluoxetine) per day and 12 mg/50 mg (olanzapine/fluoxetine) per day. The following table demonstrates the appropriate individual component doses of ZYPREXA and fluoxetine versus Symbyax. Dosage adjustments, if indicated, should be made with the individual components according to efficacy and tolerability.
Table 1: Approximate Dose Correspondence Between
Symbyaxa and the Combination of ZYPREXA and Fluoxetine
For Symbyax (mg/day) | Use in Combination | |
ZYPREXA (mg/day) | Fluoxetine (mg/day) | |
3 mg olanzapine/25 mg fluoxetine | 2.5 | 20 |
6 mg olanzapine/25 mg fluoxetine | 5 | 20 |
12 mg olanzapine/25 mg fluoxetine | 10+2.5 | 20 |
6 mg olanzapine/50 mg fluoxetine | 5 | 40+10 |
12 mg olanzapine/50 mg fluoxetine | 10+2.5 | 40+10 |
a Symbyax (olanzapine/fluoxetine HCl) is a fixed-dose combination of ZYPREXA and fluoxetine. |
While there is no body of evidence to answer the question of how long a patient treated with ZYPREXA and fluoxetine in combination should remain on it, it is generally accepted that bipolar I disorder, including the depressive episodes associated with bipolar I disorder, is a chronic illness requiring chronic treatment. The physician should periodically reexamine the need for continued pharmacotherapy.
ZYPREXA monotherapy is not indicated for the treatment of depressive episodes associated with bipolar I disorder.
ZYPREXA And Fluoxetine In Combination: Treatment Resistant Depression
When using ZYPREXA and fluoxetine in combination, also refer to the Clinical Studies section of the package insert for Symbyax.
Oral olanzapine should be administered in combination with fluoxetine once daily in the evening, without regard to meals, generally beginning with 5 mg of oral olanzapine and 20 mg of fluoxetine. Dosage adjustments, if indicated, can be made according to efficacy and tolerability within dose ranges of oral olanzapine 5 to 20 mg and fluoxetine 20 to 50 mg. Antidepressant efficacy was demonstrated with olanzapine and fluoxetine in combination in adult patients with a dose range of olanzapine 6 to 18 mg and fluoxetine 25 to 50 mg.
Safety and efficacy of olanzapine in combination with fluoxetine was determined in clinical trials supporting approval of Symbyax (fixed dose combination of olanzapine and fluoxetine). Symbyax is dosed between 3 mg/25 mg (olanzapine/fluoxetine) per day and 12 mg/50 mg (olanzapine/fluoxetine) per day. Table 1 above demonstrates the appropriate individual component doses of ZYPREXA and fluoxetine versus Symbyax. Dosage adjustments, if indicated, should be made with the individual components according to efficacy and tolerability.
While there is no body of evidence to answer the question of how long a patient treated with ZYPREXA and fluoxetine in combination should remain on it, it is generally accepted that treatment resistant depression (major depressive disorder in adult patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode) is a chronic illness requiring chronic treatment. The physician should periodically reexamine the need for continued pharmacotherapy.
Safety of co-administration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in clinical studies.
ZYPREXA monotherapy is not indicated for treatment of treatment resistant depression (major depressive disorder in patients who do not respond to 2 antidepressants of adequate dose and duration in the current episode).
ZYPREXA And Fluoxetine In Combination: Dosing In Special Populations
The starting dose of oral olanzapine 2.5-5 mg with fluoxetine 20 mg should be used for patients with a predisposition to hypotensive reactions, patients with hepatic impairment, or patients who exhibit a combination of factors that may slow the metabolism of olanzapine or fluoxetine in combination (female gender, geriatric age, nonsmoking status), or those patients who may be pharmacodynamically sensitive to olanzapine. Dosing modification may be necessary in patients who exhibit a combination of factors that may slow metabolism. When indicated, dose escalation should be performed with caution in these patients. ZYPREXA and fluoxetine in combination have not been systematically studied in patients over 65 years of age or in patients under 10 years of age.
- None with ZYPREXA monotherapy.
- When using ZYPREXA and fluoxetine in combination, also refer to the Contraindications section of the package insert for Symbyax.
- For specific information about the contraindications of lithium or valproate, refer to the Contraindications section of the package inserts for these other products.
WARNINGS
Included as part of the PRECAUTIONS section.
PRECAUTIONS
When using ZYPREXA and fluoxetine in combination, also refer to the Warnings and Precautions section of the package insert for Symbyax.
Elderly Patients With Dementia-Related Psychosis
Increased Mortality
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ZYPREXA is not approved for the treatment of patients with dementia-related psychosis.
In placebo-controlled clinical trials of elderly patients with dementia-related psychosis, the incidence of death in olanzapine-treated patients was significantly greater than placebo-treated patients (3.5% vs 1.5%, respectively).
Cerebrovascular Adverse Events (CVAE), Including Stroke
Cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, were reported in patients in trials of olanzapine in elderly patients with dementia-related psychosis. In placebo-controlled trials, there was a significantly higher incidence of cerebrovascular adverse events in patients treated with olanzapine compared to patients treated with placebo. Olanzapine is not approved for the treatment of patients with dementia-related psychosis.
Suicide
The possibility of a suicide attempt is inherent in schizophrenia and in bipolar I disorder, and close supervision of high-risk patients should accompany drug therapy. Prescriptions for olanzapine should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose.
Neuroleptic Malignant Syndrome (NMS)
A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including olanzapine. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.
The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to exclude cases where the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology.
The management of NMS should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for NMS.
If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported.
Drug Reaction With Eosinophilia And Systemic Symptoms (DRESS)
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported with olanzapine exposure. DRESS may present with a cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, fever, and/or lymphadenopathy with systemic complications such as hepatitis, nephritis, pneumonitis, myocarditis, and/or pericarditis. DRESS is sometimes fatal. Discontinue olanzapine if DRESS is suspected.
Metabolic Changes
Atypical antipsychotic drugs have been associated with metabolic changes including hyperglycemia, dyslipidemia, and weight gain. Metabolic changes may be associated with increased cardiovascular/cerebrovascular risk. Olanzapine's specific metabolic profile is presented below.
Hyperglycemia And Diabetes Mellitus
Physicians should consider the risks and benefits when prescribing olanzapine to patients with an established diagnosis of diabetes mellitus, or having borderline increased blood glucose level (fasting 100-126 mg/dL, nonfasting 140-200 mg/dL). Patients taking olanzapine should be monitored regularly for worsening of glucose control. Patients starting treatment with olanzapine should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.
Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics including olanzapine. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Epidemiological studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse reactions in patients treated with the atypical antipsychotics. While relative risk estimates are inconsistent, the association between atypical antipsychotics and increases in glucose levels appears to fall on a continuum and olanzapine appears to have a greater association than some other atypical antipsychotics.
Mean increases in blood glucose have been observed in patients treated (median exposure of 9.2 months) with olanzapine in phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). The mean increase of serum glucose (fasting and nonfasting samples) from baseline to the average of the 2 highest serum concentrations was 15.0 mg/dL.
In a study of healthy volunteers, subjects who received olanzapine (N=22) for 3 weeks had a mean increase compared to baseline in fasting blood glucose of 2.3 mg/dL. Placebo-treated subjects (N=19) had a mean increase in fasting blood glucose compared to baseline of 0.34 mg/dL.
Olanzapine Monotherapy In Adults
In an analysis of 5 placebo-controlled adult olanzapine monotherapy studies with a median treatment duration of approximately 3 weeks, olanzapine was associated with a greater mean change in fasting glucose levels compared to placebo (2.76 mg/dL versus 0.17 mg/dL). The difference in mean changes between olanzapine and placebo was greater in patients with evidence of glucose dysregulation at baseline (patients diagnosed with diabetes mellitus or related adverse reactions, patients treated with anti-diabetic agents, patients with a baseline random glucose level ≥ 200 mg/dL, and/or a baseline fasting glucose level ≥ 126 mg/dL). Olanzapine-treated patients had a greater mean HbA1c increase from baseline of 0.04% (median exposure 21 days), compared to a mean HbA1c decrease of 0.06% in placebo-treated subjects (median exposure 17 days).
In an analysis of 8 placebo-controlled studies (median treatment exposure 4-5 weeks), 6.1% of olanzapine-treated subjects (N=855) had treatment-emergent glycosuria compared to 2.8% of placebo-treated subjects (N=599). Table 2 shows short-term and long-term changes in fasting glucose levels from adult olanzapine monotherapy studies.
Table 2: Changes in Fasting Glucose Levels from Adult
Olanzapine Monotherapy Studies
Laboratory Analyte | Category Change (at least once) from Baseline | Treatment Arm | Up to 12 weeks exposure | At least 48 weeks exposure | ||
N | Patients | N | Patients | |||
Fasting Glucose | Normal to High ( < 100 mg/dL to ≥ 126 mg/dL) | Olanzapine | 543 | 2.2% | 345 | 12.8% |
Placebo | 293 | 3.4% | NAa | NAa | ||
Borderline to High ( ≥ 100 mg/dL and < 126 mg/dL to ≥ 126 mg/dL) | Olanzapine | 178 | 17.4% | 127 | 26.0% | |
Placebo | 96 | 11.5% | NAa | NAa | ||
a Not Applicable. |
The mean change in fasting glucose for patients exposed at least 48 weeks was 4.2 mg/dL (N=487). In analyses of patients who completed 9-12 months of olanzapine therapy, mean change in fasting and nonfasting glucose levels continued to increase over time.
Olanzapine Monotherapy In Adolescents
The safety and efficacy of olanzapine have not been established in patients under the age of 13 years. In an analysis of 3 placebo-controlled olanzapine monotherapy studies of adolescent patients, including those with schizophrenia (6 weeks) or bipolar I disorder (manic or mixed episodes) (3 weeks), olanzapine was associated with a greater mean change from baseline in fasting glucose levels compared to placebo  (2.68 mg/dL versus -2.59 mg/dL). The mean change in fasting glucose for adolescents exposed at least 24 weeks was 3.1 mg/dL (N=121). Table 3 shows short-term and long-term changes in fasting blood glucose from adolescent olanzapine monotherapy studies.
Table 3: Changes in Fasting Glucose Levels from
Adolescent Olanzapine Monotherapy Studies
Laboratory Analyte | Category Change (at least once) from Baseline | Treatment Arm | Up to 12 weeks exposure | At least 24 weeks exposure | ||
N | Patients | N | Patients | |||
Fasting Glucose | Normal to High ( < 100 mg/dL to ≥ 126 mg/dL) | Olanzapine | 124 | 0% | 108 | 0.9% |
Placebo | 53 | 1.9% | NAa | NAa | ||
Borderline to High ( ≥ 100 mg/dL and < 126 mg/dL to ≥ 126 mg/dL) | Olanzapine | 14 | 14.3% | 13 | 23.1% | |
Placebo | 13 | 0% | NAa | NAa | ||
a Not Applicable. |
Dyslipidemia
Undesirable alterations in lipids have been observed with olanzapine use. Clinical monitoring, including baseline and periodic follow-up lipid evaluations in patients using olanzapine, is recommended.
Clinically significant, and sometimes very high ( > 500 mg/dL), elevations in triglyceride levels have been observed with olanzapine use. Modest mean increases in total cholesterol have also been seen with olanzapine use.
Olanzapine Monotherapy In Adults
In an analysis of 5 placebo-controlled olanzapine monotherapy studies with treatment duration up to 12 weeks, olanzapine-treated patients had increases from baseline in mean fasting total cholesterol, LDL cholesterol, and triglycerides of 5.3 mg/dL, 3.0 mg/dL, and 20.8 mg/dL respectively compared to decreases from baseline in mean fasting total cholesterol, LDL cholesterol, and triglycerides of 6.1 mg/dL, 4.3 mg/dL, and 10.7 mg/dL for placebo-treated patients. For fasting HDL cholesterol, no clinically meaningful differences were observed between olanzapine-treated patients and placebo-treated patients. Mean increases in fasting lipid values (total cholesterol, LDL cholesterol, and triglycerides) were greater in patients without evidence of lipid dysregulation at baseline, where lipid dysregulation was defined as patients diagnosed with dyslipidemia or related adverse reactions, patients treated with lipid lowering agents, or patients with high baseline lipid levels.
In long-term studies (at least 48 weeks), patients had increases from baseline in mean fasting total cholesterol, LDL cholesterol, and triglycerides of 5.6 mg/dL, 2.5 mg/dL, and 18.7 mg/dL, respectively, and a mean decrease in fasting HDL cholesterol of 0.16 mg/dL. In an analysis of patients who completed 12 months of therapy, the mean nonfasting total cholesterol did not increase further after approximately 4-6 months.
The proportion of patients who had changes (at least once) in total cholesterol, LDL cholesterol or triglycerides from normal or borderline to high, or changes in HDL cholesterol from normal or borderline to low, was greater in long-term studies (at least 48 weeks) as compared with short-term studies. Table 4 shows categorical changes in fasting lipids values.
Table 4: Changes in Fasting
Lipids Values from Adult Olanzapine Monotherapy Studies
Laboratory Analyte | Category Change (at least once) from Baseline | Treatment Arm | Up to 12 weeks exposure | At least 48 weeks exposure | ||
N | Patients | N | Patients | |||
Fasting Triglycerides | Increase by ≥ 50 mg/dL | Olanzapine | 745 | 39.6% | 487 | 61.4% |
Placebo | 402 | 26.1% | NAa | NAa | ||
Normal to High ( < 150 mg/dL to ≥ 200 mg/dL) | Olanzapine | 457 | 9.2% | 293 | 32.4% | |
Placebo | 251 | 4.4% | NAa | NAa | ||
Borderline to High ( ≥ 150 mg/dL and < 200 mg/dL to ≥ 200 mg/dL) | Olanzapine | 135 | 39.3% | 75 | 70.7% | |
Placebo | 65 | 20.0% | NAa | NAa | ||
Fasting Total Cholesterol | Increase by ≥ 40 mg/dL | Olanzapine | 745 | 21.6% | 489 | 32.9% |
Placebo | 402 | 9.5% | NAa | NAa | ||
Normal to High ( < 200 mg/dL to ≥ 240 mg/dL) | Olanzapine | 392 | 2.8% | 283 | 14.8% | |
Placebo | 207 | 2.4% | NAa | NAa | ||
Borderline to High ( ≥ 200 mg/dL and < 240 mg/dL to ≥ 240 mg/dL) | Olanzapine | 222 | 23.0% | 125 | 55.2% | |
Placebo | 112 | 12.5% | NAa | NAa | ||
Fasting LDL Cholesterol | Increase by ≥ 30 mg/dL | Olanzapine | 536 | 23.7% | 483 | 39.8% |
Placebo | 304 | 14.1% | NAa | NAa | ||
Normal to High | Olanzapine | 154 | 0% | 123 | 7.3% | |
( < 100 mg/dL to ≥ 160 mg/dL) | Placebo | 82 | 1.2% | NAa | NAa | |
Borderline to High | Olanzapine | 302 | 10.6% | 284 | 31.0% | |
( ≥ 100 mg/dL and < 160 mg/dL to ≥ 160 mg/dL) | Placebo | 173 | 8.1% | NAa | NAa | |
a Not Applicable. |
In phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), over a median exposure of 9.2 months, the mean increase in triglycerides in patients taking olanzapine was 40.5 mg/dL. In phase 1 of CATIE, the mean increase in total cholesterol was 9.4 mg/dL.
Olanzapine Monotherapy In Adolescents
The safety and efficacy of olanzapine have not been established in patients under the age of 13 years. In an analysis of 3 placebo-controlled olanzapine monotherapy studies of adolescents, including those with schizophrenia (6 weeks) or bipolar I disorder (manic or mixed episodes) (3 weeks), olanzapinetreated adolescents had increases from baseline in mean fasting total cholesterol, LDL cholesterol, and triglycerides of 12.9 mg/dL, 6.5 mg/dL, and 28.4 mg/dL, respectively, compared to increases from baseline in mean fasting total cholesterol and LDL cholesterol of 1.3 mg/dL and 1.0 mg/dL, and a decrease in triglycerides of 1.1 mg/dL for placebo-treated adolescents. For fasting HDL cholesterol, no clinically meaningful differences were observed between olanzapinetreated adolescents and placebo-treated adolescents.
In long-term studies (at least 24 weeks), adolescents had increases from baseline in mean fasting total cholesterol, LDL cholesterol, and triglycerides of 5.5 mg/dL, 5.4 mg/dL, and 20.5 mg/dL, respectively, and a mean decrease in fasting HDL cholesterol of 4.5 mg/dL. Table 5 shows categorical changes in fasting lipids values in adolescents.
Table 5: Changes in Fasting
Lipids Values from Adolescent Olanzapine Monotherapy Studies
Laboratory Analyte | Category Change (at least once) from Baseline | Treatment Arm | Up to 6 weeks exposure | At least 24 weeks exposure | ||
N | Patients | N | Patients | |||
Fasting Triglycerides | Increase by ≥ 50 mg/dL | Olanzapine | 138 | 37.0% | 122 | 45.9% |
Placebo | 66 | 15.2% | NAa | NAa | ||
Normal to High ( < 90 mg/dL to > 130 mg/dL) | Olanzapine | 67 | 26.9% | 66 | 36.4% | |
Placebo | 28 | 10.7% | NAa | NAa | ||
Borderline to High ( ≥ 90 mg/dL and ≤ 130 mg/dL to > 130 mg/dL) | Olanzapine | 37 | 59.5% | 31 | 64.5% | |
Placebo | 17 | 35.3% | NAa | NAa | ||
Fasting Total Cholesterol | Increase by ≥ 40 mg/dL | Olanzapine | 138 | 14.5% | 122 | 14.8% |
Placebo | 66 | 4.5% | NAa | NAa | ||
Normal to High ( < 170 mg/dL to ≥ 200 mg/dL) | Olanzapine | 87 | 6.9% | 78 | 7.7% | |
Placebo | 43 | 2.3% | NAa | NAa | ||
Borderline to High ( ≥ 170 mg/dL and < 200 mg/dL to ≥ 200 mg/dL) | Olanzapine | 36 | 38.9% | 33 | 57.6% | |
Placebo | 13 | 7.7% | NAa | NAa | ||
Fasting LDL Cholesterol | Increase by ≥ 30 mg/dL | Olanzapine | 137 | 17.5% | 121 | 22.3% |
Placebo | 63 | 11.1% | NAa | NAa | ||
Normal to High ( < 110 mg/dL to ≥ 130 mg/dL) | Olanzapine | 98 | 5.1% | 92 | 10.9% | |
Placebo | 44 | 4.5% | NAa | NAa | ||
Borderline to High ( ≥ 110 mg/dL and < 130 mg/dL to ≥ 130 mg/dL) | Olanzapine | 29 | 48.3% | 21 | 47.6% | |
Placebo | 9 | 0% | NAa | NAa | ||
a Not Applicable. |
Weight Gain
Potential consequences of weight gain should be considered prior to starting olanzapine. Patients receiving olanzapine should receive regular monitoring of weight.
Olanzapine Monotherapy In Adults
In an analysis of 13 placebo-controlled olanzapine monotherapy studies, olanzapine-treated patients gained an average of 2.6 kg (5.7 lb) compared to an average 0.3 kg (0.6 lb) weight loss in placebo-treated patients with a median exposure of 6 weeks; 22.2% of olanzapine-treated patients gained at least 7% of their baseline weight, compared to 3% of placebo-treated patients, with a median exposure to event of 8 weeks; 4.2% of olanzapine-treated patients gained at least 15% of their baseline weight, compared to 0.3% of placebo-treated patients, with a median exposure to event of 12 weeks. Clinically significant weight gain was observed across all baseline Body Mass Index (BMI) categories. Discontinuation due to weight gain occurred in 0.2% of olanzapine-treated patients and in 0% of placebo-treated patients.
In long-term studies (at least 48 weeks), the mean weight gain was 5.6 kg (12.3 lb) (median exposure of 573 days, N=2021). The percentages of patients who gained at least 7%, 15%, or 25% of their baseline body weight with long-term exposure were 64%, 32%, and 12%, respectively. Discontinuation due to weight gain occurred in 0.4% of olanzapinetreated patients following at least 48 weeks of exposure.
Table 6 includes data on adult weight gain with olanzapine pooled from 86 clinical trials. The data in each column represent data for those patients who completed treatment periods of the durations specified.
Table 6: Weight Gain with
Olanzapine Use in Adults
Amount Gained kg (lb) | 6 Weeks (N=7465) (%) |
6 Months (N=4162) (%) |
12 Months (N=1345) (%) |
24 Months (N=474) (%) |
36 Months (N=147) (%) |
≤ 0 | 26.2 | 24.3 | 20.8 | 23.2 | 17.0 |
0 to ≤ 5 (0-11 lb) | 57.0 | 36.0 | 26.0 | 23.4 | 25.2 |
> 5 to ≤ 10 (11-22 lb) | 14.9 | 24.6 | 24.2 | 24.1 | 18.4 |
> 10 to ≤ 15 (22-33 lb) | 1.8 | 10.9 | 14.9 | 11.4 | 17.0 |
> 15 to ≤ 20 (33-44 lb) | 0.1 | 3.1 | 8.6 | 9.3 | 11.6 |
> 20 to ≤ 25 (44-55 lb) | 0 | 0.9 | 3.3 | 5.1 | 4.1 |
> 25 to ≤ 30 (55-66 lb) | 0 | 0.2 | 1.4 | 2.3 | 4.8 |
> 30 ( > 66 lb) | 0 | 0.1 | 0.8 | 1.2 | 2 |
Dose group differences with respect to weight gain have been observed. In a single 8-week randomized, double-blind, fixed-dose study comparing 10 (N=199), 20 (N=200) and 40 (N=200) mg/day of oral olanzapine in adult patients with schizophrenia or schizoaffective disorder, mean baseline to endpoint increase in weight (10 mg/day: 1.9 kg; 20 mg/day: 2.3 kg; 40 mg/day: 3 kg) was observed with significant differences between 10 vs 40 mg/day.
Olanzapine Monotherapy In Adolescents
The safety and efficacy of olanzapine have not been established in patients under the age of 13 years. Mean increase in weight in adolescents was greater than in adults. In 4 placebo-controlled trials, discontinuation due to weight gain occurred in 1% of olanzapine-treated patients, compared to 0% of placebo-treated patients.
Table 7: Weight Gain with
Olanzapine Use in Adolescents from 4 Placebo-Controlled Trials
Olanzapine-treated patients | Placebo-treated patients | |
Mean change in body weight from baseline (median exposure = 3 weeks) | 4.6 kg (10.1 lb) | 0.3 kg (0.7 lb) |
Percentage of patients who gained at least 7% of baseline body weight | 40.6% (median exposure to 7% = 4 weeks) | 9.8% (median exposure to 7% = 8 weeks) |
Percentage of patients who gained at least 15% of baseline body weight | 7.1% (median exposure to 15% = 19 weeks) | 2.7% (median exposure to 15% = 8 weeks) |
In long-term studies (at least 24 weeks), the mean weight gain was 11.2 kg (24.6 lb); (median exposure of 201 days, N=179). The percentages of adolescents who gained at least 7%, 15%, or 25% of their baseline body weight with long-term exposure were 89%, 55%, and 29%, respectively. Among adolescent patients, mean weight gain by baseline BMI category was 11.5 kg (25.3 lb), 12.1 kg (26.6 lb), and 12.7 kg (27.9 lb), respectively, for normal (N=106), overweight (N=26) and obese (N=17). Discontinuation due to weight gain occurred in 2.2% of olanzapine-treated patients following at least 24 weeks of exposure.
Table 8 shows data on adolescent weight gain with olanzapine pooled from 6 clinical trials. The data in each column represent data for those patients who completed treatment periods of the durations specified. Little clinical trial data is available on weight gain in adolescents with olanzapine beyond 6 months of treatment.
Table 8: Weight Gain with
Olanzapine Use in Adolescents
Amount Gained kg (lb) | 6 Weeks (N=243) (%) |
6 Months (N=191) (%) |
≤ 0 | 2.9 | 2.1 |
0 to ≤ 5 (0-11 lb) | 47.3 | 24.6 |
> 5 to ≤ 10 (11-22 lb) | 42.4 | 26.7 |
> 10 to ≤ 15 (22-33 lb) | 5.8 | 22.0 |
> 15 to ≤ 20 (33-44 lb) | 0.8 | 12.6 |
> 20 to ≤ 25 (44-55 lb) | 0.8 | 9.4 |
> 25 to ≤ 30 (55-66 lb) | 0 | 2.1 |
> 30 to ≤ 35 (66-77 lb) | 0 | 0 |
> 35 to ≤ 40 (77-88 lb) | 0 | 0 |
> 40 ( > 88 lb) | 0 | 0.5 |
Tardive Dyskinesia
A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown.
The risk of developing tardive dyskinesia and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses or may even arise after discontinuation of treatment.
There is no known treatment for established cases of tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.
Given these considerations, olanzapine should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients (1) who suffer from a chronic illness that is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.
If signs and symptoms of tardive dyskinesia appear in a patient on olanzapine, drug discontinuation should be considered. However, some patients may require treatment with olanzapine despite the presence of the syndrome. For specific information about the warnings of lithium or valproate, refer to the Warnings section
SIDE EFFECTS
When using ZYPREXA and fluoxetine in combination, also refer to the Adverse Reactions section of the package insert for Symbyax.
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect or predict the rates observed in practice.
Clinical Trials In Adults
The information below for olanzapine is derived from a clinical trial database for olanzapine consisting of 10,504 adult patients with approximately 4765 patient-years of exposure to olanzapine plus 722 patients with exposure to intramuscular olanzapine for injection. This database includes: (1) 2500 patients who participated in multiple-dose oral olanzapine premarketing trials in schizophrenia and Alzheimer's disease representing approximately 1122 patient-years of exposure as of February 14, 1995; (2) 182 patients who participated in oral olanzapine premarketing bipolar I disorder  (manic or mixed episodes) trials representing approximately 66 patient-years of exposure; (3) 191 patients who participated in an oral olanzapine trial of patients having various psychiatric symptoms in association with Alzheimer's disease representing approximately 29 patient-years of exposure; (4) 5788 additional patients from 88 oral olanzapine clinical trials as of December 31, 2001; (5) 1843 additional patients from 41 olanzapine clinical trials as of October 31, 2011; and (6) 722 patients who participated in intramuscular olanzapine for injection premarketing trials in agitated patients with schizophrenia, bipolar I disorder (manic or mixed episodes), or dementia. Also included below is information from the premarketing 6-week clinical study database for olanzapine in combination with lithium or valproate, consisting of 224 patients who participated in bipolar I disorder (manic or mixed episodes) trials with approximately 22 patient-years of exposure.
The conditions and duration of treatment with olanzapine varied greatly and included (in overlapping categories) open-label and double-blind phases of studies, inpatients and outpatients, fixed-dose and dose-titration studies, and short-term or longer-term exposure. Adverse reactions were assessed by collecting adverse reactions, results of physical examinations, vital signs, weights, laboratory analytes, ECGs, chest x-rays, and results of ophthalmologic examinations.
Certain portions of the discussion below relating to objective or numeric safety parameters, namely, dose-dependent adverse reactions, vital sign changes, weight gain, laboratory changes, and ECG changes are derived from studies in patients with schizophrenia and have not been duplicated for bipolar I disorder (manic or mixed episodes) or agitation. However, this information is also generally applicable to bipolar I disorder (manic or mixed episodes) and agitation.
Adverse reactions during exposure were obtained by spontaneous report and recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse reactions without first grouping similar types of reactions into a smaller number of standardized reaction categories. In the tables and tabulations that follow, MedDRA and COSTART Dictionary terminology has been used to classify reported adverse reactions.
The stated frequencies of adverse reactions represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse reaction of the type listed. A reaction was considered treatment emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation. The reported reactions do not include those reaction terms that were so general as to be uninformative. Reactions listed elsewhere in labeling may not be repeated below. It is important to emphasize that, although the reactions occurred during treatment with olanzapine, they were not necessarily caused by it. The entire label should be read to gain a complete understanding of the safety profile of olanzapine.
The prescriber should be aware that the figures in the tables and tabulations cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and nondrug factors to the adverse reactions incidence in the population studied.
Incidence Of Adverse Reactions In Short-Term, Placebo-Controlled And Combination Trials
The following findings are based on premarketing trials of (1) oral olanzapine for schizophrenia, bipolar I disorder (manic or mixed episodes), a subsequent trial of patients having various psychiatric symptoms in association with Alzheimer's disease, and premarketing combination trials, and (2) intramuscular olanzapine for injection in agitated patients with schizophrenia or bipolar I mania.
Adverse Reactions Associated With Discontinuation Of Treatment In Short-Term, Placebo-Controlled Trials
Schizophrenia - Overall, there was no difference in the incidence of discontinuation due to adverse reactions (5% for oral olanzapine vs 6% for placebo). However, discontinuations due to increases in ALT were considered to be drug related (2% for oral olanzapine vs 0% for placebo).
Bipolar I Disorder (Manic or Mixed Episodes) Monotherapy - Overall, there was no difference in the incidence of discontinuation due to adverse reactions (2% for oral olanzapine vs 2% for placebo).
Agitation - Overall, there was no difference in the incidence of discontinuation due to adverse reactions (0.4% for intramuscular olanzapine for injection vs 0% for placebo).
Adverse Reactions Associated With Discontinuation Of Treatment In Short-Term Combination Trials
Bipolar I Disorder (Manic or Mixed Episodes), Olanzapine as Adjunct to Lithium or Valproate - In a study of patients who were already tolerating either lithium or valproate as monotherapy, discontinuation rates due to adverse reactions were 11% for the combination of oral olanzapine with lithium or valproate compared to 2% for patients who remained on lithium or valproate monotherapy. Discontinuations with the combination of oral olanzapine and lithium or valproate that occurred in more than 1 patient were: somnolence (3%), weight gain (1%), and peripheral edema (1%).
Commonly Observed Adverse Reactions In Short-Term, Placebo-Controlled Trials
The most commonly observed adverse reactions associated with the use of oral olanzapine (incidence of 5% or greater) and not observed at an equivalent incidence among placebo-treated patients (olanzapine incidence at least twice that for placebo) were:
Table 9: Common Treatment-Emergent Adverse Reactions
Associated with the Use of Oral Olanzapine in 6-Week Trials - SCHIZOPHRENIA
Adverse Reaction | Olanzapine (N=248) |
Placebo (N=118) |
Postural hypotension | 5 | 2 |
Constipation | 9 | 3 |
Weight gain | 6 | 1 |
Dizziness | 11 | 4 |
Personality disordera | 8 | 4 |
Akathisia | 5 | 1 |
a Personality disorder is the COSTART term for designating nonaggressive objectionable behavior. |
Table 10: Common Treatment-Emergent Adverse Reactions
Associated with the Use of Oral Olanzapine in 3-Week and 4-Week Trials -
Bipolar I Disorder (Manic or Mixed Episodes) Percentage of Patients Reporting
Event
Adverse Reaction | Olanzapine (N=125) |
Placebo (N=129) |
Asthenia | 15 | 6 |
Dry mouth | 22 | 7 |
Constipation | 11 | 5 |
Dyspepsia | 11 | 5 |
Increased appetite | 6 | 3 |
Somnolence | 35 | 13 |
Dizziness | 18 | 6 |
Tremor | 6 | 3 |
Olanzapine Intramuscular - There was 1 adverse reaction (somnolence) observed at an incidence of 5% or greater among intramuscular olanzapine for injection-treated patients and not observed at an equivalent incidence among placebo-treated patients (olanzapine incidence at least twice that for placebo) during the placebo-controlled premarketing studies. The incidence of somnolence during the 24 hour IM treatment period in clinical trials in agitated patients with schizophrenia or bipolar I mania was 6% for intramuscular olanzapine for injection and 3% for placebo.
Adverse Reactions Occurring At An Incidence Of 2% Or More Among Oral Olanzapine-Treated Patients In Short-Term, Placebo-Controlled Trials
Table 11 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse reactions that occurred in 2% or more of patients treated with oral olanzapine (doses ≥ 2.5 mg/day) and with incidence greater than placebo who participated in the acute phase of placebo-controlled trials.
Table 11: Treatment-Emergent
Adverse Reactions: Incidence in Short-Term, Placebo-Controlled Clinical Trials
with Oral Olanzapine Percentage of Patients Reporting Event
Body System/Adverse Reaction | Percentage of Patients Reporting Event | |
Olanzapine (N=532) |
Placebo (N=294) |
|
Body as a Whole | ||
Accidental injury | 12 | 8 |
Asthenia | 10 | 9 |
Fever | 6 | 2 |
Back pain | 5 | 2 |
Chest pain | 3 | 1 |
Cardiovascular System | ||
Postural hypotension | 3 | 1 |
Tachycardia | 3 | 1 |
Hypertension | 2 | 1 |
Digestive System | ||
Dry mouth | 9 | 5 |
Constipation | 9 | 4 |
Dyspepsia | 7 | 5 |
Vomiting | 4 | 3 |
Increased appetite | 3 | 2 |
Hemic and Lymphatic System | ||
Ecchymosis | 5 | 3 |
Metabolic and Nutritional Disorders | ||
Weight gain | 5 | 3 |
Peripheral edema | 3 | 1 |
Musculoskeletal System | ||
Extremity pain (other than joint) | 5 | 3 |
Joint pain | 5 | 3 |
Nervous System | ||
Somnolence | 29 | 13 |
Insomnia | 12 | 11 |
Dizziness | 11 | 4 |
Abnormal gait | 6 | 1 |
Tremor | 4 | 3 |
Akathisia | 3 | 2 |
Hypertonia | 3 | 2 |
Articulation impairment | 2 | 1 |
Respiratory System | ||
Rhinitis | 7 | 6 |
Cough increased | 6 | 3 |
Pharyngitis | 4 | 3 |
Special Senses | ||
Amblyopia | 3 | 2 |
Urogenital System | ||
Urinary incontinence | 2 | 1 |
Urinary tract infection | 2 | 1 |
Dose Dependency Of Adverse Reactions
A dose group difference has been observed for fatigue, dizziness, weight gain and prolactin elevation. In a single 8-week randomized, double-blind, fixed-dose study comparing 10 (N=199), 20 (N=200) and 40 (N=200) mg/day of oral olanzapine in adult patients with schizophrenia or schizoaffective disorder, incidence of fatigue (10 mg/day: 1.5%; 20 mg/day: 2.1%; 40 mg/day: 6.6%) was observed with significant differences between 10 vs 40 and 20 vs 40 mg/day. The incidence of dizziness (10 mg/day: 2.6%; 20 mg/day: 1.6%; 40 mg/day: 6.6%) was observed with significant differences between 20 vs 40 mg. Dose group differences were also noted for weight gain and prolactin elevation.
The following table addresses dose relatedness for other adverse reactions using data from a schizophrenia trial involving fixed dosage ranges of oral olanzapine. It enumerates the percentage of patients with treatment-emergent adverse reactions for the 3 fixed-dose range groups and placebo. The data were analyzed using the Cochran-Armitage test, excluding the placebo group, and the table includes only those adverse reactions for which there was a trend.
Table 12: Percentage of
Patients from a Schizophrenia Trial with Treatment-Emergent Adverse Reactions
for the 3 Dose Range Groups and Placebo
Adverse Reaction | Placebo (N=68) |
Percentage of Patients Reporting Event | ||
Olanzapine 5 ± 2.5 mg/day (N=65) |
Olanzapine 10 ± 2.5 mg/day (N=64) |
Olanzapine 15 ± 2.5 mg/day (N=69) |
||
Asthenia | 15 | 8 | 9 | 20 |
Dry mouth | 4 | 3 | 5 | 13 |
Nausea | 9 | 0 | 2 | 9 |
Somnolence | 16 | 20 | 30 | 39 |
Tremor | 3 | 0 | 5 | 7 |
Commonly Observed Adverse Reactions In Short-Term Trials Of Oral Olanzapine As Adjunct To Lithium Or Valproate
In the bipolar I disorder (manic or mixed episodes) adjunct placebo-controlled trials, the most commonly observed adverse reactions associated with the combination of olanzapine and lithium or valproate (incidence of ≥ 5% and at least twice placebo) were:
Table 13: Common
Treatment-Emergent Adverse Reactions Associated with the Use of Oral Olanzapine
in 6-Week Adjunct to Lithium or Valproate Trials - Bipolar I Disorder (Manic or
Mixed Episodes)
Adverse Reaction | Percentage of Patients Reporting Event | |
Olanzapine with lithium or valproate (N=229) |
Placebo with lithium or valproate (N=115) |
|
Dry mouth | 32 | 9 |
Weight gain | 26 | 7 |
Increased appetite | 24 | 8 |
Dizziness | 14 | 7 |
Back pain | 8 | 4 |
Constipation | 8 | 4 |
Speech disorder | 7 | 1 |
Increased salivation | 6 | 2 |
Amnesia | 5 | 2 |
Paresthesia | 5 | 2 |
Adverse Reactions Occurring At An Incidence Of 2% or More among Oral Olanzapine-Treated Patients In Short-Term Trials Of Olanzapine As Adjunct To Lithium Or Valproate
Table 14 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse reactions that occurred in 2% or more of patients treated with the combination of olanzapine (doses ≥ 5 mg/day) and lithium or valproate and with incidence greater than lithium or valproate alone who participated in the acute phase of placebo-controlled combination trials.
Table 14: Treatment-Emergent
Adverse Reactions: Incidence in Short-Term, Placebo-Controlled Clinical Trials
of Oral Olanzapine as Adjunct to Lithium or Valproate
Body System/Adverse Reaction | Percentage of Patients Reporting Event | |
Olanzapine with lithium or valproate (N=229) |
Placebo with lithium or valproate (N=115) |
|
Body as a Whole | ||
Asthenia | 18 | 13 |
Back pain | 8 | 4 |
Accidental injury | 4 | 2 |
Chest pain | 3 | 2 |
Cardiovascular System | ||
Hypertension | 2 | 1 |
Digestive System | ||
Dry mouth | 32 | 9 |
Increased appetite | 24 | 8 |
Thirst | 10 | 6 |
Constipation | 8 | 4 |
Increased salivation | 6 | 2 |
Metabolic and Nutritional Disorders | ||
Weight gain | 26 | 7 |
Peripheral edema | 6 | 4 |
Edema | 2 | 1 |
Nervous System | ||
Somnolence | 52 | 27 |
Tremor | 23 | 13 |
Depression | 18 | 17 |
Dizziness | 14 | 7 |
Speech disorder | 7 | 1 |
Amnesia | 5 | 2 |
Paresthesia | 5 | 2 |
Apathy | 4 | 3 |
Confusion | 4 | 1 |
Euphoria | 3 | 2 |
Incoordination | 2 | 0 |
Respiratory System | ||
Pharyngitis | 4 | 1 |
Dyspnea | 3 | 1 |
Skin and Appendages | ||
Sweating | 3 | 1 |
Acne | 2 | 0 |
Dry skin | 2 | 0 |
Special Senses | ||
Amblyopia | 9 | 5 |
Abnormal vision | 2 | 0 |
Urogenital System | ||
Dysmenorrheaa | 2 | 0 |
Vaginitisa | 2 | 0 |
a Denominator used was for females only (olanzapine, N=128; placebo, N=51). |
For specific information about the adverse reactions observed with lithium or valproate, refer to the Adverse Reactions section of the package inserts for these other products.
Adverse Reactions Occurring At An Incidence Of 1% Or More Among Intramuscular Olanzapine For Injection-Treated Patients In Short-Term, Placebo-Controlled Trials
Table 15 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse reactions that occurred in 1% or more of patients treated with intramuscular olanzapine for injection (dose range of 2.5-10 mg/injection) and with incidence greater than placebo who participated in the short-term, placebo-controlled trials in agitated patients with schizophrenia or bipolar I mania.
Table 15: Treatment-Emergent
Adverse Reactions: Incidence in Short-Term (24 Hour), Placebo-Controlled
Clinical Trials with Intramuscular Olanzapine for Injection in Agitated
Patients with Schizophrenia or Bipolar I Mania
Body System/Adverse Reaction Body as a Whole | Percentage of Patients Reporting Event | |
Olanzapine (N=415) |
Placebo (N=150) |
|
Asthenia | 2 | 1 |
Cardiovascular System | ||
Hypotension | 2 | 0 |
Postural hypotension | 1 | 0 |
Nervous System | ||
Somnolence | 6 | 3 |
Dizziness | 4 | 2 |
Tremor | 1 | 0 |
Extrapyramidal Symptoms
The following table enumerates the percentage of patients with treatment-emergent extrapyramidal symptoms as assessed by categorical analyses of formal rating scales during acute therapy in a controlled clinical trial comparing oral olanzapine at 3 fixed doses with placebo in the treatment of schizophrenia in a 6-week trial.
Table 16: Treatment-Emergent
Extrapyramidal Symptoms Assessed by Rating Scales Incidence in a Fixed Dosage
Range, Placebo-Controlled Clinical Trial of Oral Olanzapine in Schizophrenia -
Acute Phase
Percentage of Patients Reporting Event | ||||
Placebo | Olanzapine 5 ± 2.5 mg/day | Olanzapine 10 ± 2.5 mg/day | Olanzapine 15 ± 2.5 mg/day | |
Parkinsonisma | 15 | 14 | 12 | 14 |
Akathisiab | 23 | 16 | 19 | 27 |
a Percentage of patients with a Simpson-Angus
Scale total score > 3. b Percentage of patients with a Barnes Akathisia Scale global score ≥ 2. |
The following table enumerates the percentage of patients with treatment-emergent extrapyramidal symptoms as assessed by spontaneously reported adverse reactions during acute therapy in the same controlled clinical trial comparing olanzapine at 3 fixed doses with placebo in the treatment of schizophrenia in a 6-week trial.
Table 17: Treatment-Emergent
Extrapyramidal Symptoms Assessed by Adverse Reactions Incidence in a Fixed
Dosage Range, Placebo-Controlled Clinical Trial of Oral Olanzapine in
Schizophrenia - Acute Phase
Percentage of Patients Reporting Event | ||||
Placebo (N=68) |
Olanzapine 5 ± 2.5 mg/day (N=65) |
Olanzapine 10 ± 2.5 mg/day (N=64) |
Olanzapine 15 ± 2.5 mg/day (N=69) |
|
Dystonic eventsa | 1 | 3 | 2 | 3 |
Parkinsonism eventsb | 10 | 8 | 14 | 20 |
Akathisia eventsc | 1 | 5 | 11 | 10 |
Dyskinetic eventsd | 4 | 0 | 2 | 1 |
Residual eventse | 1 | 2 | 5 | 1 |
Any extrapyramidal event | 16 | 15 | 25 | 32 |
a Patients with the following COSTART terms
were counted in this category: dystonia, generalized spasm, neck rigidity,
oculogyric crisis, opisthotonos, torticollis. b Patients with the following COSTART terms were counted in this category: akinesia, cogwheel rigidity, extrapyramidal syndrome, hypertonia, hypokinesia, masked facies, tremor. c Patients with the following COSTART terms were counted in this category: akathisia, hyperkinesia. d Patients with the following COSTART terms were counted in this category: buccoglossal syndrome, choreoathetosis, dyskinesia, tardive dyskinesia. e Patients with the following COSTART terms were counted in this category: movement disorder, myoclonus, twitching. |
The following table enumerates the percentage of adolescent patients with treatment-emergent extrapyramidal symptoms as assessed by spontaneously reported adverse reactions during acute therapy (dose range: 2.5 to 20 mg/day).
Table 18: Treatment-Emergent
Extrapyramidal Symptoms Assessed by Adverse Reactions Incidence in
Placebo-Controlled Clinical Trials of Oral Olanzapine in Schizophrenia and
Bipolar I Disorder - Adolescents
Categoriesa | Percentage of Patients Reporting Event | |
Placebo (N=89) |
Olanzapine (N=179) |
|
Dystonic events | 0 | 1 |
Parkinsonism events | 2 | 1 |
Akathisia events | 4 | 6 |
Dyskinetic events | 0 | 1 |
Nonspecific events | 0 | 4 |
Any extrapyramidal event | 6 | 10 |
a Categories are based on Standard MedDRA Queries (SMQ) for extrapyramidal symptoms as defined in MedDRA version 12.0. |
The following table enumerates the percentage of patients with treatment-emergent extrapyramidal symptoms as assessed by categorical analyses of formal rating scales during controlled clinical trials comparing fixed doses of intramuscular olanzapine for injection with placebo in agitation. Patients in each dose group could receive up to 3 injections during the trials. Patient assessments were conducted during the 24 hours following the initial dose of intramuscular olanzapine for injection.
Table 19: Treatment-Emergent
Extrapyramidal Symptoms Assessed by Rating Scales Incidence in a Fixed Dose,
Placebo-Controlled Clinical Trial of Intramuscular Olanzapine for Injection in
Agitated Patients with Schizophrenia
Placebo | Percentage of Patients Reporting Event | ||||
Olanzapine IM 2.5 mg | Olanzapine IM 5 mg | Olanzapine IM 7.5 mg | Olanzapine IM 10 mg | ||
Parkinsonisma | 0 | 0 | 0 | 0 | 3 |
Akathisiab | 0 | 0 | 5 | 0 | 0 |
a Percentage of patients with a Simpson-Angus
Scale total score > 3. b Percentage of patients with a Barnes Akathisia Scale global score ≥ 2. |
The following table enumerates the percentage of patients with treatment-emergent extrapyramidal symptoms as assessed by spontaneously reported adverse reactions in the same controlled clinical trial comparing fixed doses of intramuscular olanzapine for injection with placebo in agitated patients with schizophrenia.
Table 20: Treatment-Emergent
Extrapyramidal Symptoms Assessed by Adverse Reactions Incidence in a Fixed
Dose, Placebo-Controlled Clinical Trial of Intramuscular Olanzapine for
Injection in Agitated Patients with Schizophrenia
Percentage of Patients Reporting Event | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Placebo (N=45) |
Olanzapine IM 2.5 mg (N=48) |
Olanzapine IM 5 mg (N=45) |
Olanzapine IM 7.5 mg (N=46) |
Olanzapine IM 10 mg (N=46) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dystonic eventsa | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Parkinsonism eventsb | 0 | 4 | 2 | 0 | 0 |
Adverse Reaction | Olanzapine (N=248) |
Placebo (N=118) |
Postural hypotension | 5 | 2 |
Constipation | 9 | 3 |
Weight gain | 6 | 1 |
Dizziness | 11 | 4 |
Personality disordera | 8 | 4 |
Akathisia | 5 | 1 |
a Personality disorder is the COSTART term for designating nonaggressive objectionable behavior. |
Table 10: Common Treatment-Emergent Adverse Reactions
Associated with the Use of Oral Olanzapine in 3-Week and 4-Week Trials -
Bipolar I Disorder (Manic or Mixed Episodes) Percentage of Patients Reporting
Event
Adverse Reaction | Olanzapine (N=125) |
Placebo (N=129) |
Asthenia | 15 | 6 |
Dry mouth | 22 | 7 |
Constipation | 11 | 5 |
Dyspepsia | 11 | 5 |
Increased appetite | 6 | 3 |
Somnolence | 35 | 13 |
Dizziness | 18 | 6 |
Tremor | 6 | 3 |
Olanzapine Intramuscular - There was 1 adverse reaction (somnolence) observed at an incidence of 5% or greater among intramuscular olanzapine for injection-treated patients and not observed at an equivalent incidence among placebo-treated patients (olanzapine incidence at least twice that for placebo) during the placebo-controlled premarketing studies. The incidence of somnolence during the 24 hour IM treatment period in clinical trials in agitated patients with schizophrenia or bipolar I mania was 6% for intramuscular olanzapine for injection and 3% for placebo.
Adverse Reactions Occurring At An Incidence Of 2% Or More Among Oral Olanzapine-Treated Patients In Short-Term, Placebo-Controlled Trials
Table 11 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse reactions that occurred in 2% or more of patients treated with oral olanzapine (doses ≥ 2.5 mg/day) and with incidence greater than placebo who participated in the acute phase of placebo-controlled trials.
Table 11: Treatment-Emergent
Adverse Reactions: Incidence in Short-Term, Placebo-Controlled Clinical Trials
with Oral Olanzapine Percentage of Patients Reporting Event
Body System/Adverse Reaction | Percentage of Patients Reporting Event | |
Olanzapine (N=532) |
Placebo (N=294) |
|
Body as a Whole | ||
Accidental injury | 12 | 8 |
Asthenia | 10 | 9 |
Fever | 6 | 2 |
Back pain | 5 | 2 |
Chest pain | 3 | 1 |
Cardiovascular System | ||
Postural hypotension | 3 | 1 |
Tachycardia | 3 | 1 |
Hypertension | 2 | 1 |
Digestive System | ||
Dry mouth | 9 | 5 |
Constipation | 9 | 4 |
Dyspepsia | 7 | 5 |
Vomiting | 4 | 3 |
Increased appetite | 3 | 2 |
Hemic and Lymphatic System | ||
Ecchymosis | 5 | 3 |
Metabolic and Nutritional Disorders | ||
Weight gain | 5 | 3 |
Peripheral edema | 3 | 1 |
Musculoskeletal System | ||
Extremity pain (other than joint) | 5 | 3 |
Joint pain | 5 | 3 |
Nervous System | ||
Somnolence | 29 | 13 |
Insomnia | 12 | 11 |
Dizziness | 11 | 4 |
Abnormal gait | 6 | 1 |
Tremor | 4 | 3 |
Akathisia | 3 | 2 |
Hypertonia | 3 | 2 |
Articulation impairment | 2 | 1 |
Respiratory System | ||
Rhinitis | 7 | 6 |
Cough increased | 6 | 3 |
Pharyngitis | 4 | 3 |
Special Senses | ||
Amblyopia | 3 | 2 |
Urogenital System | ||
Urinary incontinence | 2 | 1 |
Urinary tract infection | 2 | 1 |
Dose Dependency Of Adverse Reactions
A dose group difference has been observed for fatigue, dizziness, weight gain and prolactin elevation. In a single 8-week randomized, double-blind, fixed-dose study comparing 10 (N=199), 20 (N=200) and 40 (N=200) mg/day of oral olanzapine in adult patients with schizophrenia or schizoaffective disorder, incidence of fatigue (10 mg/day: 1.5%; 20 mg/day: 2.1%; 40 mg/day: 6.6%) was observed with significant differences between 10 vs 40 and 20 vs 40 mg/day. The incidence of dizziness (10 mg/day: 2.6%; 20 mg/day: 1.6%; 40 mg/day: 6.6%) was observed with significant differences between 20 vs 40 mg. Dose group differences were also noted for weight gain and prolactin elevation.
The following table addresses dose relatedness for other adverse reactions using data from a schizophrenia trial involving fixed dosage ranges of oral olanzapine. It enumerates the percentage of patients with treatment-emergent adverse reactions for the 3 fixed-dose range groups and placebo. The data were analyzed using the Cochran-Armitage test, excluding the placebo group, and the table includes only those adverse reactions for which there was a trend.
Table 12: Percentage of
Patients from a Schizophrenia Trial with Treatment-Emergent Adverse Reactions
for the 3 Dose Range Groups and Placebo
Adverse Reaction | Placebo (N=68) |
Percentage of Patients Reporting Event | ||
Olanzapine 5 ± 2.5 mg/day (N=65) |
Olanzapine 10 ± 2.5 mg/day (N=64) |
Olanzapine 15 ± 2.5 mg/day (N=69) |
||
Asthenia | 15 | 8 | 9 | 20 |
Dry mouth | 4 | 3 | 5 | 13 |
Nausea | 9 | 0 | 2 | 9 |
Somnolence | 16 | 20 | 30 | 39 |
Tremor | 3 | 0 | 5 | 7 |
Commonly Observed Adverse Reactions In Short-Term Trials Of Oral Olanzapine As Adjunct To Lithium Or Valproate
In the bipolar I disorder (manic or mixed episodes) adjunct placebo-controlled trials, the most commonly observed adverse reactions associated with the combination of olanzapine and lithium or valproate (incidence of ≥ 5% and at least twice placebo) were:
Table 13: Common
Treatment-Emergent Adverse Reactions Associated with the Use of Oral Olanzapine
in 6-Week Adjunct to Lithium or Valproate Trials - Bipolar I Disorder (Manic or
Mixed Episodes)
Adverse Reaction | Percentage of Patients Reporting Event | |
Olanzapine with lithium or valproate (N=229) |
Placebo with lithium or valproate (N=115) |
|
Dry mouth | 32 | 9 |
Weight gain | 26 | 7 |
Increased appetite | 24 | 8 |
Dizziness | 14 | 7 |
Back pain | 8 | 4 |
Constipation | 8 | 4 |
Speech disorder | 7 | 1 |
Increased salivation | 6 | 2 |
Amnesia | 5 | 2 |
Paresthesia | 5 | 2 |
Adverse Reactions Occurring At An Incidence Of 2% or More among Oral Olanzapine-Treated Patients In Short-Term Trials Of Olanzapine As Adjunct To Lithium Or Valproate
Table 14 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse reactions that occurred in 2% or more of patients treated with the combination of olanzapine (doses ≥ 5 mg/day) and lithium or valproate and with incidence greater than lithium or valproate alone who participated in the acute phase of placebo-controlled combination trials.
Table 14: Treatment-Emergent
Adverse Reactions: Incidence in Short-Term, Placebo-Controlled Clinical Trials
of Oral Olanzapine as Adjunct to Lithium or Valproate
Body System/Adverse Reaction | Percentage of Patients Reporting Event | |
Olanzapine with lithium or valproate (N=229) |
Placebo with lithium or valproate (N=115) |
|
Body as a Whole | ||
Asthenia | 18 | 13 |
Back pain | 8 | 4 |
Accidental injury | 4 | 2 |
Chest pain | 3 | 2 |
Cardiovascular System | ||
Hypertension | 2 | 1 |
Digestive System | ||
Dry mouth | 32 | 9 |
Increased appetite | 24 | 8 |
Thirst | 10 | 6 |
Constipation | 8 | 4 |
Increased salivation | 6 | 2 |
Metabolic and Nutritional Disorders | ||
Weight gain | 26 | 7 |
Peripheral edema | 6 | 4 |
Edema | 2 | 1 |
Nervous System | ||
Somnolence | 52 | 27 |
Tremor | 23 | 13 |
Depression | 18 | 17 |
Dizziness | 14 | 7 |
Speech disorder | 7 | 1 |
Amnesia | 5 | 2 |
Paresthesia | 5 | 2 |
Apathy | 4 | 3 |
Confusion | 4 | 1 |
Euphoria | 3 | 2 |
Incoordination | 2 | 0 |
Respiratory System | ||
Pharyngitis | 4 | 1 |
Dyspnea | 3 | 1 |
Skin and Appendages | ||
Sweating | 3 | 1 |
Acne | 2 | 0 |
Dry skin | 2 | 0 |
Special Senses | ||
Amblyopia | 9 | 5 |
Abnormal vision | 2 | 0 |
Urogenital System | ||
Dysmenorrheaa | 2 | 0 |
Vaginitisa | 2 | 0 |
a Denominator used was for females only (olanzapine, N=128; placebo, N=51). |
For specific information about the adverse reactions observed with lithium or valproate, refer to the Adverse Reactions section of the package inserts for these other products.
Adverse Reactions Occurring At An Incidence Of 1% Or More Among Intramuscular Olanzapine For Injection-Treated Patients In Short-Term, Placebo-Controlled Trials
Table 15 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse reactions that occurred in 1% or more of patients treated with intramuscular olanzapine for injection (dose range of 2.5-10 mg/injection) and with incidence greater than placebo who participated in the short-term, placebo-controlled trials in agitated patients with schizophrenia or bipolar I mania.
Table 15: Treatment-Emergent
Adverse Reactions: Incidence in Short-Term (24 Hour), Placebo-Controlled
Clinical Trials with Intramuscular Olanzapine for Injection in Agitated
Patients with Schizophrenia or Bipolar I Mania
Body System/Adverse Reaction Body as a Whole | Percentage of Patients Reporting Event | |
Olanzapine (N=415) |
Placebo (N=150) |
|
Asthenia | 2 | 1 |
Cardiovascular System | ||
Hypotension | 2 | 0 |
Postural hypotension | 1 | 0 |
Nervous System | ||
Somnolence | 6 | 3 |
Dizziness | 4 | 2 |
Tremor | 1 | 0 |
Extrapyramidal Symptoms
The following table enumerates the percentage of patients with treatment-emergent extrapyramidal symptoms as assessed by categorical analyses of formal rating scales during acute therapy in a controlled clinical trial comparing oral olanzapine at 3 fixed doses with placebo in the treatment of schizophrenia in a 6-week trial.
Table 16: Treatment-Emergent
Extrapyramidal Symptoms Assessed by Rating Scales Incidence in a Fixed Dosage
Range, Placebo-Controlled Clinical Trial of Oral Olanzapine in Schizophrenia -
Acute Phase
Percentage of Patients Reporting Event | ||||
Placebo | Olanzapine 5 ± 2.5 mg/day | Olanzapine 10 ± 2.5 mg/day | Olanzapine 15 ± 2.5 mg/day | |
Parkinsonisma | 15 | 14 | 12 | 14 |
Akathisiab | 23 | 16 | 19 | 27 |
a Percentage of patients with a Simpson-Angus
Scale total score > 3. b Percentage of patients with a Barnes Akathisia Scale global score ≥ 2. |
The following table enumerates the percentage of patients with treatment-emergent extrapyramidal symptoms as assessed by spontaneously reported adverse reactions during acute therapy in the same controlled clinical trial comparing olanzapine at 3 fixed doses with placebo in the treatment of schizophrenia in a 6-week trial.
Table 17: Treatment-Emergent
Extrapyramidal Symptoms Assessed by Adverse Reactions Incidence in a Fixed
Dosage Range, Placebo-Controlled Clinical Trial of Oral Olanzapine in
Schizophrenia - Acute Phase
Percentage of Patients Reporting Event | ||||
Placebo (N=68) |
Olanzapine 5 ± 2.5 mg/day (N=65) |
Olanzapine 10 ± 2.5 mg/day (N=64) |
Olanzapine 15 ± 2.5 mg/day (N=69) |
|
Dystonic eventsa | 1 | 3 | 2 | 3 |
Parkinsonism eventsb | 10 | 8 | 14 | 20 |
Akathisia eventsc | 1 | 5 | 11 | 10 |
Dyskinetic eventsd | 4 | 0 | 2 | 1 |
Residual eventse | 1 | 2 | 5 | 1 |
Any extrapyramidal event | 16 | 15 | 25 | 32 |
a Patients with the following COSTART terms
were counted in this category: dystonia, generalized spasm, neck rigidity,
oculogyric crisis, opisthotonos, torticollis. b Patients with the following COSTART terms were counted in this category: akinesia, cogwheel rigidity, extrapyramidal syndrome, hypertonia, hypokinesia, masked facies, tremor. c Patients with the following COSTART terms were counted in this category: akathisia, hyperkinesia. d Patients with the following COSTART terms were counted in this category: buccoglossal syndrome, choreoathetosis, dyskinesia, tardive dyskinesia. e Patients with the following COSTART terms were counted in this category: movement disorder, myoclonus, twitching. |
The following table enumerates the percentage of adolescent patients with treatment-emergent extrapyramidal symptoms as assessed by spontaneously reported adverse reactions during acute therapy (dose range: 2.5 to 20 mg/day).
Table 18: Treatment-Emergent
Extrapyramidal Symptoms Assessed by Adverse Reactions Incidence in
Placebo-Controlled Clinical Trials of Oral Olanzapine in Schizophrenia and
Bipolar I Disorder - Adolescents
Categoriesa | Percentage of Patients Reporting Event | |
Placebo (N=89) |
Olanzapine (N=179) |
|
Dystonic events | 0 | 1 |
Parkinsonism events | 2 | 1 |
Akathisia events | 4 | 6 |
Dyskinetic events | 0 | 1 |
Nonspecific events | 0 | 4 |
Any extrapyramidal event | 6 | 10 |
a Categories are based on Standard MedDRA Queries (SMQ) for extrapyramidal symptoms as defined in MedDRA version 12.0. |
The following table enumerates the percentage of patients with treatment-emergent extrapyramidal symptoms as assessed by categorical analyses of formal rating scales during controlled clinical trials comparing fixed doses of intramuscular olanzapine for injection with placebo in agitation. Patients in each dose group could receive up to 3 injections during the trials. Patient assessments were conducted during the 24 hours following the initial dose of intramuscular olanzapine for injection.
Table 19: Treatment-Emergent
Extrapyramidal Symptoms Assessed by Rating Scales Incidence in a Fixed Dose,
Placebo-Controlled Clinical Trial of Intramuscular Olanzapine for Injection in
Agitated Patients with Schizophrenia
Placebo | Percentage of Patients Reporting Event | ||||
Olanzapine IM 2.5 mg | Olanzapine IM 5 mg | Olanzapine IM 7.5 mg | Olanzapine IM 10 mg | ||
Parkinsonisma | 0 | 0 | 0 | 0 | 3 |
Akathisiab | 0 | 0 | 5 | 0 | 0 |
a Percentage of patients with a Simpson-Angus
Scale total score > 3. b Percentage of patients with a Barnes Akathisia Scale global score ≥ 2. |
The following table enumerates the percentage of patients with treatment-emergent extrapyramidal symptoms as assessed by spontaneously reported adverse reactions in the same controlled clinical trial comparing fixed doses of intramuscular olanzapine for injection with placebo in agitated patients with schizophrenia.
Table 20: Treatment-Emergent
Extrapyramidal Symptoms Assessed by Adverse Reactions Incidence in a Fixed
Dose, Placebo-Controlled Clinical Trial of Intramuscular Olanzapine for
Injection in Agitated Patients with Schizophrenia
Percentage of Patients Reporting Event | |||||
Placebo (N=45) |
Olanzapine IM 2.5 mg (N=48) |
Olanzapine IM 5 mg (N=45) |
Olanzapine IM 7.5 mg (N=46) |
Olanzapine IM 10 mg (N=46) |
|
Dystonic eventsa | 0 | 0 | 0 | 0 | 0 |
Parkinsonism eventsb | 0 | 4 | 2 | 0 | 0 |